Chiauranib for Relapsed/Refractory Small Cell Lung Cancer

Chiauranib for Relapsed/Refractory Small Cell Lung Cancer
Condition:   Small-cell Lung Cancer
Intervention:   Drug: Chiauranib
Sponsors:   Chipscreen Biosciences, Ltd.;   Medelis Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 18, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments